HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugawara, Y. Articles by Wahl, R. L. Search for Related Content PubMed PubMed Citation Articles by Sugawara, Y. Articles by Wahl, R. L.

Splenic Fluorodeoxyglucose Uptake Increased by Granulocyte Colony-Stimulating Factor Therapy: PET Imaging Results

Departments of Internal Medicine and Radiology, Divisions of Nuclear Medicine and Hematology/Oncology, University of Michigan Medical Center, Ann Arbor, Michigan

Correspondence: For correspondence or reprints contact: Richard L. Wahl, MD, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Dr., B1G505C, Box 0028, Ann Arbor, MI 48109.

ABSTRACT

Using PET, we investigated the change in ¹⁸F-fluorordeoxyglucose (FDG) uptake in the spleen after granulocyte colony-stimulating factor (G-CSF) treatment. Methods: Forty-two FDG PET scans in 12 patients with locally advanced breast cancer who received G-CSF treatment were studied (12 baseline, 10 during G-CSF, 20 after G-CSF treatment). The PET images obtained at 50–60 and 60–70 min after intravenous FDG (370 MBq) injection were assessed visually and were compared with those before G-CSF treatment. For a semiquantitative index of FDG uptake, we determined the standardized uptake value calculated on the basis of predicted lean body mass (SUL) on these images, and we calculated the SUL ratios normalized to their baseline SUL values. Results: During G-CSF treatment (n = 10), 9 scans (90%) showed increased splenic FDG uptake (3 slightly, 6 substantially). After G-CSF treatment (n = 20), 13 (65%) showed no change, 7 (35%) showed slightly increased uptake, but no case showed substantially increased FDG uptake in the spleen (P = 0.0003). Out of 30 PET scans obtained during and after G-CSF treatment, 16 (53%) showed increased FDG uptake in the spleen (10 slightly, 6 substantially), whereas 26 (87%) showed increased bone marrow FDG uptake (14 slightly, 12 substantially). The FDG uptake in other normal organs (liver, blood and lung) showed no change during or after G-CSF treatment. Similar to the change in the bone marrow, the SULs in the spleen significantly increase during G-CSF treatment (baseline, 1.50 ± 0.31, versus during G-CSF, 2.69 ± 0.84; P = 0.0004), then decreased after discontinuation of G-CSF (1.65 ± 0.23). There was a significant correlation between the SUL ratios in the spleen and those in the bone marrow (r = 0.778, P < 0.0001), whereas there were no correlations between those in other organs and those in the bone marrow. Conclusion: Substantially increased FDG uptake was observed in the spleen during and after G-CSF treatment, although this change was less frequent and not as marked as the change observed in the bone marrow. The recognition and understanding of this phenomenon will be increasingly important when interpreting FDG PET images in cancer patients to avoid confusing this normal phenomenon with pathological splenic (tumor) involvement.

Key Words: breast cancer • PET • fluorodeoxyglucose • spleen • granulocyte colony-stimulating factor

This article has been cited by other articles:

				P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF]

				R. K. Doot, L. K. Dunnwald, E. K. Schubert, M. Muzi, L. M. Peterson, P. E. Kinahan, B. F. Kurland, and D. A. Mankoff Dynamic and Static Approaches to Quantifying 18F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF J. Nucl. Med., June 1, 2007; 48(6): 920 - 925. [Abstract] [Full Text] [PDF]

				M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and D. J. Straus The Role of PET in Lymphoma J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334. [Abstract] [Full Text] [PDF]

				H. A. Jacene, T. Ishimori, J. M. Engles, S. Leboulleux, V. Stearns, and R. L. Wahl Effects of Pegfilgrastim on Normal Biodistribution of 18F-FDG: Preclinical and Clinical Studies J. Nucl. Med., June 1, 2006; 47(6): 950 - 956. [Abstract] [Full Text] [PDF]

				S. KAWAI, E. IKEDA, M. SUGIYAMA, J. MATSUMOTO, T. HIGUCHI, H. ZHANG, N. KHAN, K. TOMIYOSHI, T. INOUE, H. YAMAGUCHI, et al. ENHANCEMENT OF SPLENIC GLUCOSE METABOLISM DURING ACUTE MALARIAL INFECTION: CORRELATION OF FINDINGS OF FDG-PET IMAGING WITH PATHOLOGICAL CHANGES IN A PRIMATE MODEL OF SEVERE HUMAN MALARIA. Am J Trop Med Hyg, March 1, 2006; 74(3): 353 - 360. [Abstract] [Full Text] [PDF]

				T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls RadioGraphics, January 1, 2005; 25(1): 191 - 207. [Abstract] [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				T. Higashi, S. J. Fisher, R. S. Brown, K. Nakada, G. L. Walter, and R. L. Wahl Evaluation of the Early Effect of Local Irradiation on Normal Rodent Bone Marrow Metabolism Using FDG: Preclinical PET Studies J. Nucl. Med., December 1, 2000; 41(12): 2026 - 2035. [Abstract] [Full Text] [PDF]